RxDoctor Payments Data

Marc Arnold

Nurse Practitioner · Mechanicsville, VANPI 1912042839

Payments from drug & device makers

$4,275in general payments, 2019–2025

Across 174 payments — averaging $24.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$549
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$368
  • AstraZeneca$361
  • Abbott$359
  • Novartis$312
  • Impulse Dynamics (USA) Inc.$281
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$4,25199%
  • Education$251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,275 in reported general payments places this provider in the 95th percentile of 2,166 nurse practitioner providers in Virginia.

See all nurse practitioner providers in Virginia

Medicare billing

Part B allowed, 2024
$8,662
Medicare patients
62
Services billed
94

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban459$512,818
EntrestoSacubitril/Valsartan275$341,337
FarxigaDapagliflozin Propanediol144$157,483
XareltoRivaroxaban154$153,151
JardianceEmpagliflozin94$97,871
Repatha SureclickEvolocumab65$60,368
BrilintaTicagrelor26$31,683
Ranolazine ErRanolazine105$14,452
Metoprolol Succinate886$10,728
Praluent PenAlirocumab11$9,369
Colesevelam Hcl23$8,474
Diltiazem 24hr Er (Cd)Diltiazem Hcl137$4,381
Rosuvastatin Calcium316$4,281
Valsartan130$3,902
Flecainide Acetate37$3,151

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$172$512,818459 claims
NovartisEntresto$312$341,337275 claims
AstraZenecaFarxiga, Brilinta$361$189,167170 claims
Johnson & JohnsonXarelto$34$153,151154 claims
Boehringer IngelheimJardiance$230$97,87194 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,166 nurse practitioner providers in Virginia.

Other nurse practitioner in Mechanicsville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →